Essex Investment Management Co. LLC Increases Stake in ImmuCell Co. (ICCC)

Essex Investment Management Co. LLC grew its position in shares of ImmuCell Co. (NASDAQ:ICCC) by 31.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,205 shares of the biotechnology company’s stock after buying an additional 8,494 shares during the quarter. Essex Investment Management Co. LLC’s holdings in ImmuCell were worth $309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Perritt Capital Management Inc. raised its stake in shares of ImmuCell by 15.3% in the 4th quarter. Perritt Capital Management Inc. now owns 154,300 shares of the biotechnology company’s stock valued at $1,356,000 after acquiring an additional 20,500 shares in the last quarter. Hedge funds and other institutional investors own 12.61% of the company’s stock.

ImmuCell Co. (NASDAQ:ICCC) opened at $7.06 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.75 and a debt-to-equity ratio of 0.27. ImmuCell Co. has a one year low of $5.00 and a one year high of $9.25. The firm has a market capitalization of $38.61, a P/E ratio of 705.00 and a beta of 1.03.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($0.04) earnings per share for the quarter. ImmuCell had a net margin of 0.60% and a return on equity of 0.28%.

Separately, ValuEngine raised ImmuCell from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.

COPYRIGHT VIOLATION NOTICE: “Essex Investment Management Co. LLC Increases Stake in ImmuCell Co. (ICCC)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at

About ImmuCell

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Want to see what other hedge funds are holding ICCC? Visit to get the latest 13F filings and insider trades for ImmuCell Co. (NASDAQ:ICCC).

Institutional Ownership by Quarter for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply